Michelle Dawson posts

Post published on Twitter/X on 3 Mar 2021 10:59

Twitter/X DOI work crossref Extract quoted in the post External link integrated into the post Autism terms

Structured cited links

1 cited resource

DOI work Fetched Post crossref

Bethany Oakley, Eva Loth, Declan G. Murphy (2021). Autism and mood disorders. International Review of Psychiatry, 33(3), 280-299. Informa UK Limited.

Publication date
1 Mar 2021
Identifier
10.1080/09540261.2021.1872506
Authors
Bethany Oakley, Eva Loth, Declan G. Murphy
Source
International Review of Psychiatry
Details
33(3), 280-299
Reference type
article
Publisher
Informa UK Limited
Metadata source
crossref

Abstract

Individuals with autism experience substantially higher rates of mood problems compared to the general population, which contribute to reduced quality of life and increased mortality through suicide. Here, we reviewed evidence for the clinical presentation, aetiology and therapeutic approaches for mood problems in autism. We identified a lack of validated tools for accurately identifying mood problems in individuals with autism, who may present with 'atypical' features (e.g. severe irritability). Risk factors for mood problems in autism appear to be largely overlapping with those identified in the general population, including shared genetic, environmental, cognitive, physiological/neurobiological mechanisms. However, these mechanisms are exacerbated directly/indirectly by lived experiences of autism, including increased vulnerability for chronic stress - often related to social-communication difficulties(/bullying) and sensory sensitivities. Lastly, current therapeutic approaches are based on recommendations for primary mood disorders, with little reference to the neurobiological/cognitive differences associated with autism. Thus, we recommend: 1) the development and validation of (objective) tools to identify mood problems in autism and measure therapeutic efficacy; 2) an interactive approach to investigating aetiologies in large-scale longitudinal studies, integrating different levels of analysis (e.g. cognitive, neurobiological) and lived experience; 3) testing potential treatments through high-quality (e.g. sufficiently powered, blinded) clinical trials, specifically for individuals with autism.

Study authors in this cited reference